A preservative-free intranasal formulation of varenicline (Tyrvaya) has been developed and approved in the United States for the treatment of the signs and symptoms of dry eye disease.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Champix (Pfizer); Chantix (Pfizer); Tyrvaya (Viatris)
- INDICATIONS: Smoking deterrent
- CLASS: Nicotinic antagonist
- HALF-LIFE: 24 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
SERIOUS NEUROPSYCHIATRIC EVENTS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of varenicline in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/06/2025
